FDA Approved: AMVUTTRA — Supplemental Application (Alnylam Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for AMVUTTRA (vutrisiran) submitted by Alnylam Pharmaceuticals, expanding the approved labeling for the drug.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Transthyretin-mediated Amyloidosis

Drugs mentioned

• AMVUTTRA (VUTRISIRAN)

Snippet

SUPPL AP for AMVUTTRA (VUTRISIRAN)